Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):437–443. doi: 10.1097/QAI.0000000000000855

Table 2.

Association of HIV disease status, any anal HPV infection, anal HPV 16 infection among HIV-Positive MSM

Overall No Anal HPV Infection Any Anal HPV Infection RR (95% CI) Anal HPV 16 Infection RR (95% CI)a
Characteristic N (%) N (%) N (%) N (%)*
Total N 266 (100) 14 (5) 252 (95) 31 (12)
Years since first HIV+ test 4 (±4) 3 (±2) 4 (±4) 1.0 (1.0 – 1.0) 3 (±3) 1.0 (0.8 – 1.1)
Mean CD4+ level 460 (±253) 381 (±222) 465 (±255) 1.0 (1.0 – 1.0) 467 (±256) 1.0 (1.0 – 1.0)
    <200 35 (13) 3 (9) 32 (91) 0.95 (0·8 – 1.0) 3 (9) 0.7 (0.2 – 1.3)
    200-500 125 (48) 7 (6) 118 (94) 0·98 (0.9 – 1.1) 15 (12) 0.9 (0.6 – 1.4)
    >500 103 (39) 4 (4) 99 (96) 1·0 13 (13) 1.0
Lowest CD4 count (self-report) 315 (±234) 218 (±214) 321 (±234) 1.0 (1.0 – 1.0) 331 (±235) 1.0 (1.0 – 1.0)
HIV viral load level
    Undetectable 94 (36) 6 (6) 88 (94) 1.0 9 (10) 1.0
    Detectable 170 (64) 8 (5) 162 (95) 1.0 (1.0-1.1) 22 (73) 1.2 (0.8-2.2)
Ever taken ARVs
    Yes 118 (44) 9 (8) 109 (92) 0.96 (0.9 – 1.0) 9 (8) 0.6 (0.3 – 0.95)
    No 148 (56) 5 (3) 143 (97) 1.0 22 (15) 1.0
Currently taking ARVs
    Yes 116 (44) 8 (7) 108 (93) 0.97 (0.9 – 1.0) 9 (7) 0.7 (0.3 – 1.04)
    No 150 (56) 6 (4) 144 (96) 1.0 22 (15) 1.0
Years since first initiating ARV 2 (±2) 3 (±2) 2 (±2) 0.99 (1.0 – 1.0) 1 (±1) 0.8 (0.5 – 1.01)
a

p-value, RR (95% CI) for comparison between having anal HPV 16 infection and having no anal HPV infection; p-value for categorical variable Fisher's Exact Test, from ANOVA or ranked ANOVA for continuous variables; significance of relative risks determined from general linear model likelihood ratio test.

Bold text =p-value <0.05; NE, not estimable.